"Big cracks” in Mindray's Q3 could signal weakening growth story
This article was originally published in Clinica
Executive Summary
The cracks are starting to show for Chinese firm Mindray Medical International, wrote Jefferies analyst Raj Denhoy, with the company’s “longer-term growth profile now in question.” During its third quarter, Mindray posted 15% top-line growth with sales of $296.3m – but missed analyst expectations and saw its bottom line shrink.